RESDC recently sent local state legislators letters supporting passage of a first-of-its-kind state legislation to prevent “pay-for-delay” pharmaceutical company pricing practices. The California bill seeks to prevent drug manufacturers offering patent settlements to pay generic companies to delay the introduction of lower-price medication to the market. The bill, AB 824, curbs this practice that reduces competition and arbitrarily keeps life-saving medications more expensive. View legislative information about Assembly Bill 824.
